Literature DB >> 7804386

The cardiovascular effects of bupropion and nortriptyline in depressed outpatients.

A Kiev1, H L Masco, T L Wenger, J A Johnston, S R Batey, L C Holloman.   

Abstract

The cardiovascular effects of bupropion hydrochloride and nortriptyline were compared in a double-blind, randomized, 6-week trial in adult outpatients with major depression. After a 1-week placebo phase, 58 patients were randomized to treatment with bupropion (225-450 mg/day) and 57 to nortriptyline (75-150 mg/day). Nortriptyline-treated patients had statistically significant heart rate increases at each assessment as determined by RR intervals on electrocardiogram (14.5-18 bpm). Bupropion-treated patients had small but statistically significant increases in supine diastolic blood pressure of 5.6 mm Hg on day 7 and 7.5 mm Hg on day 28. A few patients in each treatment group had orthostatic changes, but only nortriptyline-treated patients had symptomatic orthostatic hypotension. A slowing of cardiac conduction and possibly of rate-corrected repolarization occurred in patients treated with nortriptyline that did not occur in patients treated with bupropion. Compared to nortriptyline, bupropion appears to have a wider safety margin with regard to cardiovascular effects. This may be particularly true in the elderly, in patients with preexisting cardiovascular disease, or in overdose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7804386     DOI: 10.3109/10401239409148989

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  10 in total

Review 1.  Depression and heart disease: evidence of a link, and its therapeutic implications.

Authors:  Wei Jiang; Ranga R K Krishnan; Christopher M O'Connor
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia.

Authors:  Charles E Leonard; Warren B Bilker; Craig Newcomb; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-28       Impact factor: 2.890

3.  Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.

Authors:  Berit Packert Jensen; Rebecca Lee Roberts; Ritva Vyas; Gitte Bonke; David L Jardine; Evan James Begg
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

4.  Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns.

Authors:  Carla Carratalá-Ros; Régulo Olivares-García; Andrea Martínez-Verdú; Edgar Arias-Sandoval; John D Salamone; Mercè Correa
Journal:  Psychopharmacology (Berl)       Date:  2021-09-09       Impact factor: 4.415

5.  Bupropion response on sleep quality in patients with depression: implications for increased cardiovascular disease risk.

Authors:  Preetam J Schramm; Russell E Poland; Uma Rao
Journal:  Eur Neuropsychopharmacol       Date:  2013-10-11       Impact factor: 4.600

Review 6.  Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits.

Authors:  J Taylor Hays; Jon O Ebbert
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 7.  Antidepressants and cardiovascular adverse events: A narrative review.

Authors:  Mohammad Hassan Nezafati; Mohammad Vojdanparast; Pouya Nezafati
Journal:  ARYA Atheroscler       Date:  2015-09

Review 8.  Psychological and Psychopharmacological Interventions in Psychocardiology.

Authors:  Kai G Kahl; Britta Stapel; Christoph U Correll
Journal:  Front Psychiatry       Date:  2022-03-16       Impact factor: 4.157

9.  QT interval and antidepressant use: a cross sectional study of electronic health records.

Authors:  Victor M Castro; Caitlin C Clements; Shawn N Murphy; Vivian S Gainer; Maurizio Fava; Jeffrey B Weilburg; Jane L Erb; Susanne E Churchill; Isaac S Kohane; Dan V Iosifescu; Jordan W Smoller; Roy H Perlis
Journal:  BMJ       Date:  2013-01-29

10.  Treatment of affective disorders in cardiac disease.

Authors:  Nicole Mavrides; Charles B Nemeroff
Journal:  Dialogues Clin Neurosci       Date:  2015-06       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.